NCT02847091 - Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

July 29, 2016

Primary Completion Date

November 9, 2017

Study Completion Date

November 9, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Ipragliflozin

Oral administration, 50mg once daily

DRUG

Insulin

Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).

Trial Locations (15)

Unknown

Site JP00007, Gunma

Site JP00008, Hiroshima

Site JP00009, Hyōgo

Site JP00010, Kanagawa

Site JP00003, Mie

Site JP00004, Osaka

Site JP00015, Shiga

Site JP00002, Tochigi

Site JP00005, Tochigi

Site JP00013, Tochigi

Site JP00001, Tokyo

Site JP00006, Tokyo

Site JP00011, Tokyo

Site JP00012, Tokyo

Site JP00014, Tokyo